Urolead is a preclinical CRO offering tumorgraft-based services

in the urological sphere :


We provide pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo pharmacological models and in vitro assays, using human urologic tumors xenografted in mice.

  • Scientific and clinical expertise
  • Powerful know-how and tools for orthotopic and subcutaneous xenografts
  • A very large bank of samples, in terms of quantity and diversity of urologic tumors and cancer cell lines
  • Informed consent and clinical history of each patient
  • Proof of concept in patient-derived xenograft (PDX) models
  • Molecular characterization and translational research using pharmaco-imaging, analysis of target expression and signaling pathways (Western-Blot, ELISA), investigation of specific genes (RT-PCR) …
  • Histological analysis
  • Biomarkers identification for personalized medicine
  • Pharmacological characterization with relevant standards of care